125 related articles for article (PubMed ID: 19781376)
1. Endostatin derivative angiogenesis inhibitors.
Zheng MJ
Chin Med J (Engl); 2009 Aug; 122(16):1947-51. PubMed ID: 19781376
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
[TBL] [Abstract][Full Text] [Related]
3. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Feng Y; Liu C; Cao J; Mu G; Wang F
J Biochem; 2008 Aug; 144(2):207-13. PubMed ID: 18463113
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug.
Tan H; Mu G; Zhu W; Liu J; Wang F
Biol Pharm Bull; 2011; 34(4):545-50. PubMed ID: 21467643
[TBL] [Abstract][Full Text] [Related]
5. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin.
Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D
Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
7. Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice.
Schaffhauser B; Veikkola T; Strittmatter K; Antoniadis H; Alitalo K; Christofori G
J Leukoc Biol; 2006 Oct; 80(4):669-76. PubMed ID: 16793908
[TBL] [Abstract][Full Text] [Related]
8. Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin.
Sun F; Shaikh AS; Wang J; Gao H; Yang Z; Wang Z; Li Y; Wang F; Tan H
Curr Pharm Biotechnol; 2018; 19(12):996-1004. PubMed ID: 30761959
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo.
Schuch G; Oliveira-Ferrer L; Loges S; Laack E; Bokemeyer C; Hossfeld DK; Fiedler W; Ergun S
Leukemia; 2005 Aug; 19(8):1312-7. PubMed ID: 15931265
[TBL] [Abstract][Full Text] [Related]
10. [Vascular endothelial growth factor and the effects of endostatin on the inhibition of tumor angiogenesis in treating hepatocarcinomas].
Deng JY; He S
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):313-4. PubMed ID: 15850529
[No Abstract] [Full Text] [Related]
11. [Endostatin in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice].
Yao HC; Jin DJ; Sun YN; Ren MH; Li XD
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Jul; 39(7):394-8. PubMed ID: 15469109
[TBL] [Abstract][Full Text] [Related]
12. [Research of cloning, expression of human endostatin gene and its inhibition effects to the glioma in vivo].
Zhang X; Wu J; Fei Z
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):783-7. PubMed ID: 11798965
[TBL] [Abstract][Full Text] [Related]
13. [Intravesical perfusion of recombinant adeno-associated virus-endostatin in treatment of bladder cancer: experiments with mice].
Lu BX; Han RF; Tang Y; Lei MD; Li SZ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3157-8. PubMed ID: 19159603
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the mysteries of endostatin.
Fu Y; Tang H; Huang Y; Song N; Luo Y
IUBMB Life; 2009 Jun; 61(6):613-26. PubMed ID: 19472178
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic factor endostatin in osteosarcoma.
Kim HS; Lim SJ; Park YK
APMIS; 2009 Oct; 117(10):716-23. PubMed ID: 19775339
[TBL] [Abstract][Full Text] [Related]
17. Anticancer treatment of endostatin gene therapy by targeting tumor neovasculature in C57/BL mice.
Jia S; Zhu F; Li H; He F; Xiu R
Clin Hemorheol Microcirc; 2000; 23(2-4):251-7. PubMed ID: 11321448
[TBL] [Abstract][Full Text] [Related]
18. Continuous and high-level in vivo delivery of endostatin from recombinant cells encapsulated in TheraCyte immunoisolation devices.
Malavasi NV; Rodrigues DB; Chammas R; Chura-Chambi RM; Barbuto JA; Balduino K; Nonogaki S; Morganti L
Cell Transplant; 2010; 19(3):269-77. PubMed ID: 19951460
[TBL] [Abstract][Full Text] [Related]
19. What "helps" tumors evade vascular targeting treatment?
Si ZC; Liu J
Chin Med J (Engl); 2008 May; 121(9):844-9. PubMed ID: 18701052
[TBL] [Abstract][Full Text] [Related]
20. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.
Lee TY; Tjin Tham Sjin RM; Movahedi S; Ahmed B; Pravda EA; Lo KM; Gillies SD; Folkman J; Javaherian K
Clin Cancer Res; 2008 Mar; 14(5):1487-93. PubMed ID: 18316573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
